Marshall Wace
TENX icon

Marshall Wace’s Tenax Therapeutics TENX Stock Holding History

Marshall Wace’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.52M Buy
585,578
+233,006
+66% +$2.98M 0.01% 1100
2026
Q1 		$5.64M Buy
352,572
+54,419
+18% +$736K 0.01% 1246
2025
Q4 		$3.63M Buy
298,153
+120,944
+68% +$1.05M ﹤0.01% 1299
2025
Q3 		$1.35M Buy
+177,209
New +$1.08M ﹤0.01% 1806

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Marshall Wace's TENX Position: Q2 2026 in Review

Marshall Wace increased its Tenax Therapeutics (TENX) stake by 66% in Q2 2026, buying an estimated $2.98M and bringing the position to 585,578 shares worth $8.52M. The position accounts for 0.01% of the portfolio, ranked #1100.

Marshall Wace first reported a position in TENX in Q3 2025 and has held it in 4 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Marshall Wace held 585,578 shares of Tenax Therapeutics worth $8.52M as of Q2 2026.
  • Marshall Wace bought 233,006 Tenax Therapeutics shares in Q2 2026, an estimated $2.98M.
  • Tenax Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1100 holding.
  • Marshall Wace first reported a position in Tenax Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.